News
Public · Published
Krystal Biotech Is Maintained at Buy by TD Cowen
TD Cowen maintained a Buy rating on Krystal Biotech while cutting its price target to $380.00 per share from $403.00 per share.
Published:
Updated:
What happened
TD Cowen maintained a Buy rating on Krystal Biotech while cutting its price target to $380.00 per share from $403.00 per share.
Confirmed
Global impact / market context
A lower price target means the analyst still expects gains but a smaller upside than before. Investors often read this as slightly reduced confidence in future growth, even though the Buy rating itself was kept unchanged.
Analyst inference
Sell-side price targets are estimates of where a stock could trade, not guarantees. A cut alongside a maintained Buy rating suggests a modest reassessment of value rather than a changed view on the company's prospects.
Analyst inference
What to watch
- Whether other analysts follow TD Cowen in lowering their price targets for Krystal Biotech, which would signal broader expectations of slower growth. Confirmed
- Future analyst reports could raise the price target again if company results beat expectations, which would reverse the direction of this revision. Proposed
- Watch the gap between the $380 target and the current share price, since a narrow gap could mean less upside priced in for investors. Analyst inference
Evidence
- Original source link unavailable